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Jonathan R Kerr MD, DSc, MRCPath Honorary Senior Lecturer in Virology University College London Medical School Human parvovirus B 19 was discovered in 19751. The first clinically significant illness associated with B 19 infection was hypoplastic crisis in children with sickie-cell anaemia2. Development of specific serological assays showed that patients with fifth disease (erythema infectiosum) also had acute B19 infection3; an aetiology that is now widely accepted.
Human parvovirus B 19 is a member of the genus Erythrovirus of the family Parvoviridae. B19 is a small single-stranded DNA virus, whose genome is a single linear molecule of only 5596 nucleotides; composed of an internal coding sequence of 4830 nt, flanked by the terminal repeat sequences of 383 nt each. The major nonstructural protein, NS 1, is encoded by the left side of the genome, and is essential for viral replication. Structural proteins, VP1 and VP2, are encoded by the right side of the genome and form the viral capsid. Parvovirus B 19 has not been shown to infect other animals, and the other animal parvoviruses have not been shown to infect humans. B 19 infection is common in humans, with a seroprevalence in developed countries of 5% in children, 60% in blood donors and 85% or more in the elderly. In temperate climates, there is an increased prevalence from late winter to early summer and increased infection rates every four to five years. B 19 is transmitted in the community by the respiratory route causing infection both sporadically and in outbreaks, which are apparent in schools. Transmission has also occurred among medical laboratory staff working with native virus. B 19 virus can also be found in donated blood, the incidence of which is estimated between 1:3300 and 1 :50,000, and infection has been transmitted by clotting factor concentrates. Although nosocomial transmission and resultant outbreaks in both paediatric and adult wards have been documented, this is infrequent 4 infection has also been associated with fetal hydrops, congenital red cell aplasia, vasculitis syndromes, glomerulonephritis with nephrotic syndrome, meningitis, encephalopathy, peripheral neuropathy, myocarditis, hepatitis, systemic lupus erythematosus, necrotising histiocytic lymphadenitis (Kikuchi's disease), pulmonary disease following paediatric heart transplantation, conjunctivitis, Kawasaki disease, congenital abnormalities and chronic fatigue syndrome4
An outbreak of B19 infection in Northern Ireland
My work began with the description of an outbreak of B19 infection in Northern Ireland. Testing patient serum using an in-house enzymeimmunoassay assay (EIA) for anti-B19 IgM, 133 cases of acute B19 infection were diagnosed by the Regional Virus Laboratory from 1984 to July 1991. An increased prevalence (103 of 133 cases) occurred during [1989] [1990] . Of the total 133 cases, the ratio of female to male was 3.4: 1. The age range was 4-63 years with a mean of 28 years. Clinical manifestations of infection from 1984 -1991 included rash (n=22), arthralgia (n=35), rash and arthralgia (n=70), aplastic crisis in patients with shortened red cell survival (n=3), fetal death following maternal infection (n=l), HenochSchonlein purpura (n=1), and lymphadenopathy (n=l) . This outbreak coincided with an outbreak in England and Wales'.
Study of the incidence of fetal death in B19-infected pregnant women.
Although B 19 was known to cause fetal death, the incidence of this following maternal B 19 infection was unknown. During 1989, the outbreak year, we collected and later tested the serum from 2400 pregnant women at 12 weeks gestation for the presence of anti-B 19 IgM by enzymeimmunoassay. Eight of these were positive. We followed these pregnancies and found that one resulted in spontaneous abortion at 26 weeks. The incidence of fetal death following maternal infection was therefore 12.5%, in general agreement with the major UK study of 186 pregnancies which showed a 9.2% incidence of fetal death. No congenital abnormalities were noted in the 7 surviving infants, either at birth or at 3 years of age5. capsid proteins by avidin-biotin immunohistochemistry using monoclonal antibody, 3H8. These sections were then stained by a double-fluorescent labelling technique using 3H8 linked to Texas Red followed by a monoclonal antibody to P antigen linked to fluorescein. In all 3 cases an identical pattern of cellular distribution of the two antigens was seen, providing further evidence for P as the virus receptor ( Figure 1 
Study of the molecular epidemiology of parvovirus B19
The dominant influences on the clinical manifestations of B 19 infection are those of the host. Namely, age, presence of anti-B 19 antibody, immunocompetence, red cell fragility, and blood group P antigen status. However, it is possible that the make-up of a particular B 19 strain may also contribute9. To study the molecular epidemiology of B 19 infection, we developed a viral typing method using PCR -singlestranded conformational polymorphism (SSCP) assay. A nested PCR method was developed using oligonucleotide primers specific for a region within the B 19 non-structural gene. The first reaction amplified a 369 bp fragment, and the second amplified an internal 284 bp fragment (B19 nucleotides 1399-1682). This 284 bp fragment, after visualisation on agarose gel electrophoresis was then typed using SSCP. The principle of SSCP is that electrophoretic mobility of a DNA molecule in a gel is sensitive to both its size and shape. Therefore, a mutated sequence causes altered folding which is detected as a change in mobility. And in general, the method has a higher sensitivity for short fragments of 100 -200 bases'0. The method was optimised to 100% sensitivity, and was able to detect a single mutation in the 284 bp fragment. The method was then applied to 50 virus isolates from patients with different symptoms and geographical locations.
Five types were demonstrated, each of which had a unique nucleotide sequence. In all, 6 mutations were detected, all of which were silent, consistent with the B19 Parvovirus 
